Table 3.
Association between CA IX expression, cleaved caspase 3 expression, TP53 mutation status and clinicopathological parameters of NSCLC patients.
| Patient characteristic | CA IX protein expression | Cleaved caspase 3 protein expression | TP53 gene mutation analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| - | + | ++ | P-value | - | + | P-value | WT | MT | P-value | |
| Tissue | ||||||||||
| Control sample | 14 (88.0%) | 2 (12.0%) | 0 (0.0%) | < 0.001 | 10 (62.5%) | 6 (37.5%) | 0.427 | / | / | / |
| Tumor sample | 4 (4.3%) | 56 (59.6%) | 34 (36.2%) | 49 (50.5%) | 48 (49.5%) | 40 (58.0%) | 29 (42.0%) | |||
| Age | ||||||||||
| < 60 years | 2 (50.0%) | 28 (50.0%) | 17 (50.0%) | 1.000 | 24 (49.0%) | 23 (47.9%) | 1.000 | 19 (47.5%) | 14 (48.3%) | 1.000 |
| > 60 years | 2 (50.0%) | 28 (50.0%) | 17 (50.0%) | 25 (51.0%) | 25 (52.1%) | 21 (52.5%) | 15 (51.7%) | |||
| Gender | ||||||||||
| Female | 2 (50.0%) | 38 (67.9%) | 20 (58.8%) | 0.579 | 34 (69.4%) | 30 (62.5%) | 0.525 | 28 (70.0%) | 21 (72.4%) | 1.000 |
| Male | 2 (50.0%) | 18 (32.1%) | 14 (41.2%) | 15 (30.6%) | 18 (37.5%) | 12 (30.0%) | 8 (27.6%) | |||
| Smoking behavior | ||||||||||
| Non-smoker | 0 (0.0%) | 2 (4.2%) | 5 (17.2%) | 0.124 | 5 (11.9%) | 2 (4.9%) | 0.433 | 4 (12.5%) | 1 (3.8%) | 0.367 |
| Smoker | 3 (100%) | 46 (95.8%) | 24 (82.8%) | 37 (88.1%) | 39 (95.1%) | 28 (87.5%) | 25 (96.2%) | |||
| Clinical stage | ||||||||||
| I | 3 (75.0%) | 25 (44.6%) | 13 (38.2%) | 0.247 | 18 (36.7%) | 25 (52.1%) | 0.064 | 16 (40.0%) | 11 (37.9%) | 0.990 |
| II | 0 (0.0%) | 18 (32.1%) | 8 (23.5%) | 17 (34.7%) | 9 (18.8%) | 11 (27.5%) | 9 (31.0%) | |||
| III | 0 0.0%) | 11 (19.6%) | 10 (29.4%) | 9 (18.4%) | 13 (27.1%) | 9 (22.5%) | 6 (20.7%) | |||
| IV | 1 (25.0%) | 2 (3.6%) | 3 (8.8%) | 5 (10.2%) | 1 (2.1%) | 4 (10.0%) | 3 (10.3%) | |||
| Tumor classification | ||||||||||
| T1 | 1 (25.0%) | 21 (37.5%) | 10 (29.4%) | 0.562 | 12 (24.5%) | 20 (41.7%) | 0.321 | 13 (32.5%) | 7 (24.1%) | 0.796 |
| T2 | 3 (75.0%) | 18 (32.1%) | 15 (44.1%) | 22 (44.9%) | 15 (31.3%) | 15 (37.5%) | 11 (37.9%) | |||
| T3 | 0 (0.0%) | 14 (25.0%) | 6 (17.6%) | 12 (24.5%) | 10 (20.8%) | 10 (25.0%) | 10 (34.5%) | |||
| T4 | 0 (0.0%) | 3 (5.4%) | 3 (8.8%) | 3 (6.1%) | 3 (6.3%) | 2 (5.0%) | 1 (3.4%) | |||
| N0 | 3 (75.0%) | 41 (73.2%) | 19 (55.9%) | 0.349 | 31 (63.3%) | 35 (72.9%) | 0.315 | 27 (67.5%) | 19 (65.5%) | 0.720 |
| N1 | 0 (0.0%) | 9 (16.1%) | 10 (29.4%) | 12 (24.5%) | 6 (12.5%) | 7 (17.5%) | 7 (24.1%) | |||
| N2 | 1 (25.0%) | 6 (10.7%) | 5 (14.7%) | 6 (12.2%) | 7 (14.5%) | 6 (15.0%) | 3 (10.3%) | |||
| M0 | 3 (75.0%) | 53 (94.6%) | 31 (91.2%) | 0.327 | 43 (87.8%) | 47 (97.9%) | 0.111 | 36 (90.0%) | 26 (89.7%) | 1.000 |
| M1 | 1 (25.0%) | 3 (5.4%) | 3 (8.8%) | 6 (12.2%) | 1 (2.1%) | 4 (10.0%) | 3 (10.3%) | |||
| Differentiation | ||||||||||
| Poor | 0 (0.0%) | 17 (30.4%) | 8 (23.5%) | 0.074 | 10 (20.4%) | 17 (35.4%) | 0.155 | 11 (27.5%) | 8 (27.6%) | 0.893 |
| Moderate | 3 (75.0%) | 22 (39.3%) | 8 (23.5%) | 21 (42.9%) | 13 (27.1%) | 13 (32.5%) | 8 (27.6%) | |||
| Well | 1 (25.0%) | 17 (30.4%) | 18 (62.9%) | 18 (36.7%) | 18 (37.5%) | 16 (40.0%) | 13 (44.8%) | |||
| Metastasis during follow-up | ||||||||||
| No | 2 (50.0%) | 33 (58.9%) | 13 (38.2%) | 0.163 | 23 (46.9%) | 28 (58.3%) | 0.312 | 19 (47.5%) | 16 (55.2%) | 0.628 |
| Yes | 2 (50.0%) | 23 (41.1%) | 21 (61.8%) | 26 (53.1%) | 20 (41.7%) | 21 (52.5%) | 13 (44.8%) | |||
Upper row: CA IX expression, cleaved caspase 3 expression and TP53 mutations in control samples versus tumor samples. Other rows: associations between CA IX expression, cleaved caspase 3 expression or TP53 mutations in tumor samples and clinicopathological parameters of NSCLC patients. For CA IX staining: - negative, + weak/moderate positive, ++ strong positive. For cleaved caspase 3 staining: - < 5% positive cells, + > 5% positive cells. For TP53 status: WT wild type, MT mutant.